Home | Contact Us | About Us | Site Map
Miracle II Products | Suggested Uses | M II Testimonials | Order Miracle II | Health News | Links | Business Opportunity | Refer-A-Friend | Vitalzym | Garden of Life | GIA Wellness | Harmony Formulas | U-Fucoidan | Zymessence
Systemic Enzymes
Serrapeptase vs.
Vitalzym Ingredients
Vitalzym Dosing
Vitalzym Media
Vitalzym Practitioners
Research
Detox Reactions
Testimonials
References
FAQ
Enzyme Books



Vitalzym™ References


Vitalzym

References

  1. Buck JE, Phillips N. Trial of Chymoral in professional footballers. Br J Clin Pract.1970 Sep;24(9):375-7.
  2. Craig RP. The quantitative evaluation of the use of oral proteolytic enzymes in the treatment of sprained ankles. Injury. 1975 May;6(4):313-6.
  3. Fisher JD, Weeks RL, Curry WM, Hrinda ME, Rosen LL. Effects of an oral enzyme preparation, Chymoral, upon serum proteins associated with injury (acute phase reactants) in man. J Med. 1974;5(5):258-73.
  4. France LH. Treatment of injuries with orally administered Varidase as compared to Chymoral and Tanderil. Praxis. 1968 May 14;57(19):683-5.
  5. Gal P, Tecl F, Skotakova J, Mach V. Systemic enzyme therapy in the treatment of supracondylar fractures of the humerus in children. Rozhl Chir. 1998 Dec;77(12):574-6.
  6. Hingorani K. Oral enzyme therapy in severe back pain. Br J Clin Pract. 1968 May 5;22(5):209-10.
  7. Rathgeber WF. The use of proteolytic enzymes (chymoral) in sporting injuries. S Afr Med J. 1971 Feb 13;45(7):181-3.
  8. Schwinger O. Results of oral enzyme therapy in wounds of muscles, tendons and bones after accidents. Wien Med Wochenschr. 1970 Sep 5;120(36):603-5.
  9. Duskova M, Wald M. Orally administered proteases in aesthetic surgery. Aesthetic Plast Surg. 1999 Jan-Feb;23(1):41-4.
  10. Hoernecke R, Doenicke A. Perioperative enzyme therapy. A significant supplement to postoperative pain therapy? Anaesthesist. 1993 Dec;42(12):856-61.
  11. Lie KK, Larsen RD, Posch JL. Therapeutic value of oral proteolytic enzymes following hand surgery. Arch Surg. 1969 Jan;98(1):103-4.
  12. Mazzone A, Catalani M, Costanzo M, Drusian A, Mandoli A, Russo S, Guarini E, Vesperini G. Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo. J Int Med Res. 1990; 18(5):379-88.
  13. Mazzone A, et al. Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double blind, randomized trial versus placebo. J Int Med Res. 1990; 18(5):379-88.
  14. Aso T et al. Breast engorgement and its treatment: Clinical effects of Danzen an anti-inflammatory enzyme preparation. The world of Obstetrics and Gynecology (Japanese). 1981; 33:371-9.
  15. Petry, Judy J. "Nutritional supplements and surgical patients." AORN Journal (June 1997).
  16. Kelly, G.S. "Bromelain: A Literature Review and Discussion of Its Therapeutic Applications." Alternative Medicine Review (November 1, 1996).
    1. Metzig, C et al Bromelain Proteases reduce human platelet aggregation in vitro, adhesion to bovine endothelial cells and thrombus formation in rat vessels in vivo. In Vivo 13 (1): 7-12 Jan-Feb 1999.
  17. Starley, I. F.; Mohammed, P.; Schneider, G.; Bickler, S. W. The treatment of paediatric burns using topical papaya. Burns 1999 nov 25 (7) 636-9
  18. Wilhelmi, G. Effect of O-(beta-hydroxyethyl)-rutiside on wound healing in the rat. J pharmacology 1979 19(2):82-85.

References Serrapeptase vs Non-Steroidal

1. Raskin JB. Gastrointestinal effects of nonsteroidal anti-inflammatory therapy. Am J Med. 1999; 106 (5B):3S-12S.

2. No author listed. Regular Use of Pain Relievers Can Have Dangerous Results. Kaleidoscope Interactive News, American Medical Association media briefing. July 24, 1997.

3. Fung HB, Kirschenbaum, HL. Selective cyclooxygenase-2 inhibitors for the treatment of arthritis. ClinTher. 1999; 21(7):1131-57.

4. Geis GS. Update on clinical developments withcelecoxib, a new specific COX-2 inhibitor: what can we expect? Scand J RheumatolSuppl. 1999; 109:31-7.

5. Cheatum DE, Arvanitakis C, Gumpel M, Stead H, Geis GS. An endoscopic study of gastroduodenal lesions induced by nonsteroidal anti-inflammatory drugs. ClinTher. 1999; 21(6):992-1003.

6. Tibble JA, Sigthorsson G, Foster R, Scott D, Fagerhol MK, Roseth A, Bjarnason I. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut. 1999; 45(3):362-6.

7. Dingle JT. The effects of NSAID on the matrix of human articular cartilages. ZRheumatol. 1999; 58(3):125-9.

8. Murphy PJ, Badia P, Myers BL, BoeckerMR, Wright KP Jr. Nonsteroidal anti-inflammatory drugs affect normal sleep patterns in humans. PhysiolBehav. 1994; 55(6):1063-6.

9. Metz SA, Robertson RP, Fujimoto WY. Inhibition of prostaglandin E synthesis augments glucose-induced insulin secretion in cultured pancreas. Diabetes. 1981; 30(7):551-7.

10. Marriott C. Modification in the rheological properties of mucus by drugs. Adv Exp Med Biol. 1982; 144:75-84.

11. Tokumine F, Sunagawa T, Shiohira Y, Nakamoto T, Miyazato F, Muto Y. Drug-associatedcholelithiasis: a case of sulindac stone formation and the incorporation of sulindac metabolites into the gallstones. Am JGastroenterol.1999;94(8):2285-8.

12. Jiang HK, Chang DM. Non-steroidal anti-inflammatory drugs with adverse psychiatric reactions: five case reports. ClinRheumatol. 1999;18(4):339-45.

13. Fung HB, Kirschenbaum, HL. Selective cyclooxygenase-2 inhibitors for the treatment of arthritis. ClinTher. 1999; 21(7):1131-57.

14. FDA MedWatch: The FDA Medical Products Reporting Program. May 12, 1999. FDA Talk Paper.

15. Moriya N, Nakata M, Nakamura M, Takaoka M, Iwasa S, Kato K, Kakinuma A. Intestinal absorption of serrapeptase (TSP) in rats. Biotechnol ApplBiochem. 1994; 20(Pt1):101-8.

16. Miyata, K. Intestinal absorption of Serratia Peptidase. J ApplBiochem. 1980;2:111-16.

17. Perna L. Osservazionl Clniche sui traitamento in osppio cleco con Serratio peptidasl nella neifre perenna naila ninite cronica nacutizzata consinusopattia, nella bronchia cronica nacutizzata. Rlv Pat Clin Tuberc Penumol. 1985;56:509-516.

18. Mazzone A, et al. Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: amulticentre, double-blind, randomized trial versus placebo. J Int Med Res. 1990; 18(5):379-88.

19. Aso T et al. Breast engorgement and its treatment: Clinical effects of Danzen an anti-inflammatory enzyme preparation. The world of Obstetrics and Gynecology (Japanese). 1981; 33:371-9.

20. Esch PM, Gerngross H, Fabian A. Reduction of postoperative swelling. Objective measurement of swelling of the upper ankle joint in treatment withserrapeptase-a prospective study (German). Fortschr Med. 1989;107(4):67-8, 71-2.

21. Kee WH, Tan SL, Lee V, SalmonYM. The treatment of breast engorgement with Serrapeptase (Danzen): a randomized double-blind controlled trial. Singapore Med J. 1989;30(1):48-54.

22. Koyama A, Mori J, Tokuda H, Waku M, Anno H, Katayama T, Murakami K, Komatsu H, Hirata M, Arai T, et al. Augmentation by serrapeptase of tissue permeation by cefotiam (Japanese). Jpn JAntibiot. 1986; 39(3):761-71.

23. Majima Y, Inagaki M, Hirata K, Takeuchi K, Morishita A, Sakakura Y. The effect of an orally administered proteolytic enzyme on the elasticity and viscosity of nasal mucus. ArchOtorhinolaryngol. 1988;244(6):355-9.

24. Brewer Science Library website. 1999.

25. Tomoda K, and Miyatam K. Some information on the composition of trachael secretions before and after the administration ofDanzen. Exper Ther. 1972; 477:9-16.

26. Kase Y, et al. A new method for evaluating mucolytic expectorant activity and its application to two proteolytic enzymes, serratiopeptidase andseaprose. Arznelrnitteltorachung. 1982; 32:374-378.

28. Selan L, Berlutti F, Passariello C, Comodi-BallantiMR, Thaller MC. Proteolytic enzymes: a new treatment strategy for prosthetic infections? Antimicrob AgentsChemother. 1993; 37(12):2618-21.

 

Learn More

 

Last updated:

Copyright 2014 | TMN Health